Table 2 Baseline characteristics of TCGA-LIHC patients
From: A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma
Clinical features | Number (%) | Clinical features | Number (%) |
|---|---|---|---|
Follow-up time (months) | 26.7 ± 23.9 | AJCC stage | |
Survival status | Â | Â Stage I | 170 (46.6%) |
 Alive | 235 (64.4%) |  Stage II | 84 (23.0%) |
 Dead | 130 (35.6%) |  Stage III | 83 (22.7%) |
Age | 59.7 ± 13.4 |  Stage IV | 4 (1.1%) |
Sex | Â | Â Not applicable | 24 (6.6%) |
 Male | 246 (67.4%) | T classification | |
 Female | 119 (32.6%) |  T1 | 180 (49.3%) |
History of other malignancy | Â | Â T2 | 91 (24.9%) |
 No | 331 (90.7%) |  T3 | 78 (21.4%) |
 Yes | 34 (9.3%) |  T4 | 13 (3.6%) |
History of neoadjuvant treatment | Â | Â TX | 1 (0.3%) |
 No | 363 (99.5%) |  Not applicable | 2 (0.5%) |
 Yes | 2 (0.5%) | N classification | |
History of radiation treatment | Â | Â N0 | 248 (67.9%) |
 No | 238 (65.2%) |  N1 | 4 (1.1%) |
 Yes | 4 (1.1%) |  NX | 112 (30.7%) |
 Not applicable | 123 (33.7%) |  Not applicable | 1 (0.3%) |
History of chemotherapy | Â | M classification | |
 No | 222 (60.8%) |  M0 | 263 (72.1%) |
 Yes | 14 (3.8%) |  M1 | 3 (0.8%) |
 Not applicable | 129 (35.3%) |  MX | 99 (27.1%) |
History of ablation embolization | Â | Grade | |
 No | 230 (63.0%) |  G1 | 55 (15.1%) |
 Yes | 13 (3.6%) |  G2 | 175 (47.9%) |
 Not applicable | 122 (33.4%) |  G3 | 118 (32.3%) |
History of hepatic carcinoma risk factory | Â | Â G4 | 12 (3.3%) |
 No history of primary risk factors | 91 (24.9%) |  Not applicable | 5 (1.4%) |
 Alcohol consumption | 115 (31.5%) | Vascular invasion | |
 Hepatitis B | 102 (27.9%) |  No | 205 (56.2%) |
 Hepatitis C | 55 (15.1%) |  Micro | 90 (24.7%) |
 Non-alcoholic fatty liver disease | 19 (5.2%) |  Macro | 16 (4.4%) |
 Hemochromatosis | 6 (1.6%) |  Not applicable | 54 (14.8%) |
 Other | 30 (8.2%) | Relapse | |
 Not available | 18 (4.9%) |  No | 172 (47.1%) |
Residual tumor | Â Yes | 94 (25.8%) | |
 RO | 320 (87.7%) |  Not applicable | 99 (27.1%) |
 R1 | 17 (4.7%) | Histological diagnosis | |
 R2 | 1 (0.3%) |  Hepatocellular carcinoma | 355 (97.3%) |
 RX | 20 (5.5%) |  Fibrolamellar carcinoma | 3 (0.8%) |
 Not applicable | 7 (1.9%) |  Hepatocholangiocarcinoma | 7 (1.9%) |